Publications
2024
Sorting lung tumor volumes from 4D-MRI data using an automatic tumor-based signal reduces stitching artifacts.
Warren, M., Barrett, A., Bhalla, N., Brada, M., Chuter, R., Cobben, D., . . . Fenwick, J. D. (2024). Sorting lung tumor volumes from 4D-MRI data using an automatic tumor-based signal reduces stitching artifacts.. Journal of applied clinical medical physics, e14262. doi:10.1002/acm2.14262
2023
OC-0779 Reconstruction of lung tumour volumes from 4D-MRI: the use of a tumour-derived respiratory signal
Warren, M., Barrett, A., Bhalla, N., Brada, M., Cobben, D., McClelland, J., . . . Fenwick, J. (2023). OC-0779 Reconstruction of lung tumour volumes from 4D-MRI: the use of a tumour-derived respiratory signal. Radiotherapy and Oncology, 182, S648-S650. doi:10.1016/s0167-8140(23)08720-0
2022
Robust Comprehensive Dataset Provides Pause for Thought
Brada, M., Forbes, H., Ashley, S., & Fenwick, J. (2022). Robust Comprehensive Dataset Provides Pause for Thought. JOURNAL OF THORACIC ONCOLOGY, 17(6), E56-E57. doi:10.1016/j.jtho.2022.03.017
Improving Outcomes in NSCLC: Optimum Dose Fractionation in Radical Radiotherapy Matters.
Brada, M., Forbes, H., Ashley, S., & Fenwick, J. (2022). Improving Outcomes in NSCLC: Optimum Dose Fractionation in Radical Radiotherapy Matters.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 17(4), 532-543. doi:10.1016/j.jtho.2022.01.006
2021
Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial
Saran, F., Welsh, L., James, A., McBain, C., Gattamaneni, R., Jefferies, S., . . . Brada, M. (2021). Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial. JOURNAL OF NEURO-ONCOLOGY, 155(3), 307-317. doi:10.1007/s11060-021-03877-6
Cardiac-sparing radiotherapy for locally advanced non-small cell lung cancer
Turtle, L., Bhalla, N., Willett, A., Biggar, R., Leadbetter, J., Georgiou, G., . . . Fenwick, J. D. (2021). Cardiac-sparing radiotherapy for locally advanced non-small cell lung cancer. RADIATION ONCOLOGY, 16(1). doi:10.1186/s13014-021-01824-3
ESTRO ACROP guideline for target volume delineation of skull base tumors
Combs, S. E., Baumert, B. G., Bendszus, M., Bozzao, A., Brada, M., Fariselli, L., . . . Minniti, G. (2021). ESTRO ACROP guideline for target volume delineation of skull base tumors. RADIOTHERAPY AND ONCOLOGY, 156, 80-94. doi:10.1016/j.radonc.2020.11.014
2020
Dyspnea in Patients Receiving Radical Radiotherapy for Non-Small Cell Lung Cancer: A Prospective Study
Sardaro, A., McDonald, F., Bardoscia, L., Lavrenkov, K., Singh, S., Ashley, S., . . . Brada, M. (2020). Dyspnea in Patients Receiving Radical Radiotherapy for Non-Small Cell Lung Cancer: A Prospective Study. FRONTIERS IN ONCOLOGY, 10. doi:10.3389/fonc.2020.594590
2019
Integrated treatment of brain metastases
Rosenfelder, N., & Brada, M. (2019). Integrated treatment of brain metastases. CURRENT OPINION IN ONCOLOGY, 31(6), 501-507. doi:10.1097/CCO.0000000000000573
Feasibility of cardiac sparing in isotoxic dose escalated radiotherapy for NSCLC
Turtle, L., Willett, A., Leadbetter, J., Brada, M., & Fenwick, J. (2019). Feasibility of cardiac sparing in isotoxic dose escalated radiotherapy for NSCLC. In RADIOTHERAPY AND ONCOLOGY Vol. 133 (pp. S157). doi:10.1016/S0167-8140(19)30727-3
Improving outcomes in non-small cell lung cancer; population analysis of radical radiotherapy
Brada, M., Ball, C., Mitchell, S., Forbes, H., & Ashley, S. (2019). Improving outcomes in non-small cell lung cancer; population analysis of radical radiotherapy. RADIOTHERAPY AND ONCOLOGY, 132, 204-210. doi:10.1016/j.radonc.2018.10.015
Incidence and evolution of imaging changes on cone-beam CT during and after radical radiotherapy for non-small cell lung cancer
Clarke, E., Curtis, J., & Brada, M. (2019). Incidence and evolution of imaging changes on cone-beam CT during and after radical radiotherapy for non-small cell lung cancer. Radiotherapy and Oncology.
2018
Nurse-Led Telehealth Clinic in Treatment Monitoring and Follow Up
Cubbin, S., & Brada, M. (2018). Nurse-Led Telehealth Clinic in Treatment Monitoring and Follow Up. In JOURNAL OF THORACIC ONCOLOGY Vol. 13 (pp. S416-S417). doi:10.1016/j.jtho.2018.08.461
Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer
Basu, B., Krebs, M. G., Sundar, R., Wilson, R. H., Spicer, J., Jones, R., . . . Banerji, U. (2018). Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. ANNALS OF ONCOLOGY, 29(9), 1918-1925. doi:10.1093/annonc/mdy245
Phase I study of afatinib and radiotherapy (RT) with or without temozolomide (TMZ) in newly diagnosed glioblastoma (GB).
Saran, F., Welsh, L., James, A., McBain, C., Gattamaneni, R., Jefferies, S., . . . Brada, M. (2018). Phase I study of afatinib and radiotherapy (RT) with or without temozolomide (TMZ) in newly diagnosed glioblastoma (GB).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36. doi:10.1200/JCO.2018.36.15_suppl.2036
Combining immunotherapy and radiotherapy in lung cancer
Bhalla, N., Brooker, R., & Brada, M. (2018). Combining immunotherapy and radiotherapy in lung cancer. Journal of Thoracic Disease, 10, S1447-S1460. doi:10.21037/jtd.2018.05.107
A PHASE I TRIAL OF AFATINIB AND RADIOTHERAPY (RT) WITH OR WITHOUT TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
Saran, F., James, A., McBain, C., Jefferies, S., Harris, F., Cseh, A., . . . Brada, M. (2018). A PHASE I TRIAL OF AFATINIB AND RADIOTHERAPY (RT) WITH OR WITHOUT TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM). In NEURO-ONCOLOGY Vol. 20 (pp. 20). Retrieved from https://www.webofscience.com/
2017
TAX-TORC: A phase I trial of vistusertib (AZD2O14) in combination with weekly paclitaxel with integrated pharmacodynamic (PD) and molecular characterization (MC) studies.
Sundar, R., Basu, B., Wilson, R. H., Spicer, J. F., Jones, R. H., Krebs, M., . . . Banerji, U. (2017). TAX-TORC: A phase I trial of vistusertib (AZD2O14) in combination with weekly paclitaxel with integrated pharmacodynamic (PD) and molecular characterization (MC) studies.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35. doi:10.1200/JCO.2017.35.15_suppl.2571
Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO)
Soffietti, R., Abacioglu, U., Baumert, B., Combs, S. E., Kinhult, S., Kros, J. M., . . . Weller, M. (2017). Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). NEURO-ONCOLOGY, 19(2), 162-174. doi:10.1093/neuonc/now241
TAX-TORC: The Novel Combination of Weekly Paclitaxel and the Dual mTORC1/2 Inhibitor AZD2014 for the Treatment of Squamous NSCLC
Krebs, M., Spicer, J., Steele, N., Talbot, D., Brada, M., Wilson, R., . . . Yap, T. (2017). TAX-TORC: The Novel Combination of Weekly Paclitaxel and the Dual mTORC1/2 Inhibitor AZD2014 for the Treatment of Squamous NSCLC. In JOURNAL OF THORACIC ONCOLOGY Vol. 12 (pp. S1272-S1273). doi:10.1016/j.jtho.2016.11.1798
2016
Brain metastases
Jyoti, B., Balkhi Alam, F., Hofer, S., & Brada, M. (2016). Brain metastases. In Unknown Book (pp. 589-592). Wiley. doi:10.1002/9781118777329.ch144
Precision oncology: origins, optimism, and potential
Prasad, V., Fojo, T., & Brada, M. (2016). Precision oncology: origins, optimism, and potential. LANCET ONCOLOGY, 17(2), E81-E86. doi:10.1016/S1470-2045(15)00620-8
ESTRO-ACROP guideline "target delineation of glioblastomas"
Niyazi, M., Brada, M., Chalmers, A. J., Combs, S. E., Erridge, S. C., Fiorentino, A., . . . Belka, C. (2016). ESTRO-ACROP guideline "target delineation of glioblastomas". RADIOTHERAPY AND ONCOLOGY, 118(1), 35-42. doi:10.1016/j.radonc.2015.12.003
2015
Glioma
Weller, M., Wick, W., Aldape, K., Brada, M., Berger, M., Pfister, S. M., . . . Reifenberger, G. (2015). Glioma. NATURE REVIEWS DISEASE PRIMERS, 1. doi:10.1038/nrdp.2015.17
SABR in NSCLC - The beginning of the end or the end of the beginning?
Brada, M., Pope, A., & Baumann, M. (2015). SABR in NSCLC - The beginning of the end or the end of the beginning?. RADIOTHERAPY AND ONCOLOGY, 114(2), 135-137. doi:10.1016/j.radonc.2015.01.012
Against the motion
Brada, M. (2015). Against the motion. In RADIOTHERAPY AND ONCOLOGY Vol. 115 (pp. S169). Retrieved from https://www.webofscience.com/
New Developments in Intracranial Stereotactic Radiotherapy for Metastases
Pinkham, M. B., Whitfield, G. A., & Brada, M. (2015). New Developments in Intracranial Stereotactic Radiotherapy for Metastases. CLINICAL ONCOLOGY, 27(5), 316-323. doi:10.1016/j.clon.2015.01.007
The definition of an auditable and complete dataset for lung cancer patients - the RTTis role
Blair, D., Brada, M., Clarke, E., Baker, C. R., Reilly, A. J., & Baker, A. F. (2015). The definition of an auditable and complete dataset for lung cancer patients - the RTTis role. In RADIOTHERAPY AND ONCOLOGY Vol. 115 (pp. S716-S717). Retrieved from https://www.webofscience.com/
2014
High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Stupp, R., Brada, M., van den Bent, M. J., Tonn, J. -C., Pentheroudakis, G., & ESMO, G. W. G. (2014). High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ANNALS OF ONCOLOGY, 25, 93-101. doi:10.1093/annonc/mdu050
Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial
Collins, V. P., Ichimura, K., Di, Y., Pearson, D., Chan, R., Thompson, L. C., . . . Collaborators, B. (2014). Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial. ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2. doi:10.1186/2051-5960-2-68
Pituitary radiotherapy
Ajithkumar, T., & Brada, M. (2014). Pituitary radiotherapy. In Endocrinology in Clinical Practice, Second Edition (pp. 85-102).
Cone beam CT verification for active breathing control (ABC)-gated radiotherapy for lung cancer
Yeoh, K. -W., McNair, H. A., McDonald, F., Hawkins, M., Hansen, V. N., Ramos, M., . . . Brada, M. (2014). Cone beam CT verification for active breathing control (ABC)-gated radiotherapy for lung cancer. ACTA ONCOLOGICA, 53(5), 716-719. doi:10.3109/0284186X.2013.861610
Is current technology improving outcomes with radiation therapy for gliomas?
Brada, M., & Haylock, B. (2014). Is current technology improving outcomes with radiation therapy for gliomas?. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, e89-e94. doi:10.14694/edbook_am.2014.34.e89
Position statement on ethics, equipoise and research on charged particle radiation therapy
Sheehan, M., Timlin, C., Peach, K., Binik, A., Puthenparampil, W., Lodge, M., . . . Weijer, C. (2014). Position statement on ethics, equipoise and research on charged particle radiation therapy. JOURNAL OF MEDICAL ETHICS, 40(8), 572-575. doi:10.1136/medethics-2012-101290
The legend of cytomegalovirus and glioblastoma lives on
Weller, M., Soffietti, R., & Brada, M. (2014). The legend of cytomegalovirus and glioblastoma lives on. NEURO-ONCOLOGY, 16(1), 166. doi:10.1093/neuonc/not204